Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...

There was little variation between the different time windows used in the TRE groups. Magnetic resonance imaging (MRI) scans showed no differences across the groups in the reduction of the visceral ...

Zircaix, a PET imaging drug for ccRCC, has been submitted for FDA approval and received Breakthrough designation, potentially allowing priority review. The phase 3 ZIRCON trial showed Zircaix's high ...